Skip to main content
SpringerLink
Log in

Studien mit Psychopharmaka

  • Chapter
Handbuch der psychiatrischen Pharmakotherapie

  • 7324 Accesses

Zusammenfassung

Aus heutiger Sicht liest sich die klinische Erforschung der ersten modernen Psychopharmaka bis zur Markteinführung unglaublich. Der französische Pharmahersteller Rhône-Poulenc entschloss sich Ende 1951, Chlorpromazin nach ersten Erfahrungen in der Anästhesiologie auch in psychiatrischen Indikationen einzusetzen . Delay und Deniker erhielten das Medikament zur Behandlung von Manikern im Februar 1952; erste Berichte und Publikationen über Einzelfälle sowie eine offene Studie an 20 Patienten erschienen im Mai und Juni 1952 (Deniker 1988, S. 122f). Im Herbst 1952 wurde das Medikament für die Behandlung von schweren psychischen Störungen, bei denen deutliche vegetative Syndrome nachweisbar sind, zugelassen (Staehelin u. Kielholz 1953).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • AMG (2004) Zwölftes Gesetz zur Änderung des Arzneimittelgesetzes, Bundesgesetzblatt 2004 Teil I Nr. 41, S 2031–2053

    Google Scholar 

  • Aroll B, Elley CR, Fishman T et al (2009) Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 8(3): CD007954

    Google Scholar 

  • AVP (2005) Pharmakovigilanz: Empfehlungen zur Meldung unerwünschter Arzneimittelwirkungen durch die Ärzteschaft. Arzneiverordnung in der Praxis; Bd 32, Sonderheft 1: 3–29

    Google Scholar 

  • Baldwin D, Broich K, Fritze J et al (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253: 22–28

    Article  PubMed  Google Scholar 

  • Benkert O (1995) Klinische Prüfungen bei einwilligungsunfähigen Patienten. Nervenarzt 66: 864–868

    CAS  PubMed  Google Scholar 

  • Benkert O, Maier W (1990) The necessity of placebo application in psychotropic drug trials. Pharmacopsychiatry 23: 203–206

    Article  CAS  PubMed  Google Scholar 

  • Broich K; Committee for Medical Products for Human Use (2009) Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. Eur Neuropsychopharmacol 19: 305–308

    Article  CAS  PubMed  Google Scholar 

  • CIPS (Collegium Internationale Psychiatriae Scalarum) (2005) Internationale Skalen für Psychiatrie, 5. Aufl. Beltz-Test, Göttingen

    Google Scholar 

  • Citrome L (2010) Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 122: 39–48

    Article  PubMed  Google Scholar 

  • Clarenbach P, Benes H (2006) Das Restless-Legs-Syndrom. Uni-Med, Bremen

    Google Scholar 

  • Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd edn. Lawrence Earlbaum, Hillsdale, NJ

    Google Scholar 

  • De la Fuente-Fernández R, Schulzer M, Stoessl AJ (2002) The placebo effect in enurological disorders. Lancet Neurol 1: 85–91

    Article  Google Scholar 

  • Deniker P (1988) Die Geschichte der Neuroleptika. In: Linde OK (Hrsg) Pharmakopsychiatrie im Wandel der Zeit. Tilia-Verlag Mensch und Medizin, Klingenmünster, S 119–133

    Google Scholar 

  • Di Masi JA, Grabowski HG, Vernon J (2004) R&D costs and returns by therapeutic category. Drug Inf J 38: 211–233

    Google Scholar 

  • Ellenberg SS, Temple R (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 133: 464–470

    Article  CAS  PubMed  Google Scholar 

  • EMA (The European Agency for the Evaluation of Medicinal Products) (1997) ICH Topic E 6. Guideline for Good Clinical Practice: Note for Guidance on Good Clinical Practice. (CPMP/ICH/135/95). London: 17 January 1997 (http://www.EMA.europa.eu/pdfs/human/ich/013595en.pdf)

  • Emanuel EJ, Miller FG (2001) The ethics of placebo-controlled trials – a middle ground. N Engl J Med 345: 915–919

    Article  CAS  PubMed  Google Scholar 

  • European Commission (2005) Commission directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing of importation of such product (»GCP-Directive«). Brussels, 8 April 2005. Official Journal L 91, 9/4/2005, pp 13–19 (http://www.pharmacos.eudra.org/F2/eudralex/vol-1/DIR_2005_28/DIR_2005_28_EN.pdf)

  • European Parliament and Council (2001) Directive 2001/20/EC of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (»Clinical Trials Directive« CTD). Luxembourg, 4 April 2001. Official Journal L 121, 1/5/2001, pp 34–44 (http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/dir_2001_20/dir_2001_20_de.pdf )

  • Fahn S, Elton RL and members of the UPRDRS Development Committee (1987) The Unified Parkinson’s Disesae Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease. Macmillan Healthcare Information, Forham Park, NJ, pp 152–163

    Google Scholar 

  • Fergusson D, Doucette S, Glass KC et al (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Br Med J 330: 396–402

    Article  CAS  Google Scholar 

  • Finnis DG, Kaptchuk TJ, Miller F, Benedetti F (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375: 686–695

    Article  Google Scholar 

  • Fischer T (2008) Das Data Monitoring Committee: Die dritte Säule in der methodischen Durchführung von klinischen Prüfungen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 51(7): 793–796

    Article  PubMed  Google Scholar 

  • Fleischhacker WW, Burns T; European Group For Research In Schizophrenia (2002) Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe. Psychopharmacology (Berl) 162: 82–84

    Article  CAS  Google Scholar 

  • Fleischhacker WW, Czobor P, Hummer M et al (2003) Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 60: 458–464

    Article  PubMed  Google Scholar 

  • Fountoulakis KN, Möller HJ (2011) Efficac1y of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neurpsychopharmacol 14: 405–412

    Article  CAS  Google Scholar 

  • Fritze J, Moller HJ (2001) Design of clinical trials of antidepressants: should a placebo control arm be included? CNS Drugs 15: 755–764

    Article  CAS  PubMed  Google Scholar 

  • GCP-Verordnung (Verordnung über die Anwendung der Guten Klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Arzneimitteln zur Anwendung am Menschen – GCP-V), Bundesgesetzblatt 2004 Teil I Nr. 42, S 2081–2091

    Google Scholar 

  • Gibbons RD, Clard DC, Kupfer DJ (1993) Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatry 27: 259–273

    CAS  Google Scholar 

  • Grünbaum A (1981) The placebo concept. Beh Res Ther 19: 157–167

    Article  Google Scholar 

  • Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. Br Med J 330(7488): 385

    Article  CAS  Google Scholar 

  • Helmchen H, Lauter H (1995) Dürfen Ärzte mit Demenzkranken forschen? Thieme, Stuttgart

    Google Scholar 

  • Heres S, Davis J, Maino K et al (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163: 185–194

    Article  PubMed  Google Scholar 

  • Hopewell S, Clarke M, Moher D et al; CONSORT Group (2008) CONSORT for reporting randomised trials in journal and conference abstracts 371: 281–283

    Google Scholar 

  • Jones PB, Barnes TR, Davies L et al (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 63: 1079–1087

    Article  CAS  PubMed  Google Scholar 

  • Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57: 311–317

    Article  CAS  PubMed  Google Scholar 

  • Khan A, Khan SR, Leventhal RM, Brown WA (2001) Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am J Psychiatry 158: 1449–1454

    Article  CAS  PubMed  Google Scholar 

  • Khan A, Khan S, Kolts R, Brown WA (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160: 790–792

    Article  PubMed  Google Scholar 

  • Khan A, Bhat A, Kolts R et al (2010) Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 16: 217–226

    Article  PubMed  Google Scholar 

  • Kirsch I, Deacon BJ, Huedo-Medina TB et al (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45

    Article  PubMed Central  PubMed  Google Scholar 

  • Kopec JA, Abrahamowicz M, Esdaile JM (1993) Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol 46: 959–971

    Article  CAS  PubMed  Google Scholar 

  • Lam RW, Kennedy SH (2005) Using metaanalysis to evaluate evidence: practical tips and traps. Can J Psychiatry 50: 167–174

    PubMed  Google Scholar 

  • Leber PD (1989) Hazards of inference: The Active Control Investigation. Epilepsia 30(1): S57-S63

    Article  PubMed  Google Scholar 

  • Licinio J, Wong ML (2005) Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Discov 4: 165–171

    Article  CAS  PubMed  Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia http://www.ncbi.nlm.nih.gov/pubmed/16172203353: 1209–1223

  • Linde OK (Hrsg) (1988) Pharmakopsychiatrie im Wandel der Zeit - Erlebnisse und Ergebnisse. Tilia Verlag – Mensch und Medizin, Klingenmünster

    Google Scholar 

  • Linden M, Baier D, Beitinger H et al (1994) Leitlinien zur Durchführung von Anwendungsbeobachtungen (AWB) in der Psychpharmakotherapie. Nervenarzt 65: 638–644

    CAS  PubMed  Google Scholar 

  • Maier W, Möller HJ (2010) Meta-analyses: a method to maximise the evidence from clinical studies? Eur Arch Psychiatry Clin Neurosci 260: 17–23

    Article  PubMed  Google Scholar 

  • McLean S (2005) Do substance P and the NK1 receptor have a role in depression and anxiety? Curr Pharm Des 11: 1529–1547

    Article  CAS  PubMed  Google Scholar 

  • Melander H, Salmonson T, Abadie E, von Zwieten-Boot B (2008) A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur J Neuropsychopharmacol 18: 623–627

    Article  CAS  Google Scholar 

  • Meyer RE, Salzman C, Youngstrom EA et al (2010) Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 71: e1-e21

    Article  PubMed  Google Scholar 

  • Moher D, Cook DJ, Eastwood S et al (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896–1900

    Article  CAS  PubMed  Google Scholar 

  • Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials) (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285: 1987–1991

    Article  CAS  PubMed  Google Scholar 

  • Möller HJ (2001) Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 251(2): II/13-II/20

    Article  Google Scholar 

  • Möller HJ (2008) Do effectiveness (»real world«) studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 258: 257–270

    Article  PubMed  Google Scholar 

  • Möller HJ (2009) Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 10: 6–26

    Article  PubMed  Google Scholar 

  • Möller HJ, Broich K (2010) Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neursci 260: 3–16

    Article  Google Scholar 

  • Möller HJ, Maier W (2010) Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci. 260: 25–39

    Article  PubMed  Google Scholar 

  • Möller HJ, Baldwin DS, Goodwin G et al; WPA Section on Pharmacopsychiatry (2008) Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci. 258(Suppl 3): 3–23

    Article  PubMed  Google Scholar 

  • Moncrieff J, Kirsch I (2005) Efficacy of antidepressants in adults. BMJ 331: 155–157

    Article  PubMed Central  PubMed  Google Scholar 

  • Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev (1): CD003012

    PubMed  Google Scholar 

  • Montgomery SA (1994) Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 4: 283–284

    Article  CAS  Google Scholar 

  • Montgomery SA (1999a) Alternatives to placebo-controlled trials in psychiatry. ECNP Consensus Meeting, September 26, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 9: 265–269

    Article  CAS  PubMed  Google Scholar 

  • Montgomery SA (1999b) The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 9: 271–276

    Article  CAS  PubMed  Google Scholar 

  • Montgomery SA, Möller HJ (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 24: 111–118

    Article  PubMed  Google Scholar 

  • Müller MJ, Szegedi A (2002) Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials. J Clin Psychopharmacol 22: 318–325

    Article  PubMed  Google Scholar 

  • National Institute for Clinical Excellence (NICE) 2004) Depression, management of depression in primary and secondary care. Clinical Practice Guideline No. 23. NICE, London

    Google Scholar 

  • Nedopil N, Aldenhoff J, Amelung K et al (1999) Einwilligungsfähigkeit bei klinischen Prüfungen. Stellungnahme der Arbeitsgruppe »Ethische und rechtliche Fragen« der Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Pharmacopsychiatry 32 (May): I-IV

    CAS  PubMed  Google Scholar 

  • Paykell ES (1990) Placebo-controlled studies in depression: necessity and feasibility. In: Benkert O, Maier W, Rickels K (Hrsg). Methodology of the evaluation of psychotropic drugs. Springer, Berlin Heidelberg New York, pp 73–81

    Chapter  Google Scholar 

  • Posner K, Oquendo MA, Gould M et al (2007) Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA‘s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164: 1035–1043

    Article  PubMed Central  PubMed  Google Scholar 

  • Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4: 353–365

    Article  CAS  PubMed  Google Scholar 

  • Riedel M, Möller HJ, Obermeier M et al (2010) Response and remission criteria in major depression–a validation of current practice. J Psychiatr Res 44: 1063–1068

    Article  PubMed  Google Scholar 

  • San Miguel MT, Vargas E (2006) Drug evaluation and approval process in the European Union. Arthritis Care Res 55: 12–14

    Article  Google Scholar 

  • Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 1: 100–107

    Article  PubMed Central  PubMed  Google Scholar 

  • Staehelin JE, Kielholz P (1953) Largactil, ein neues vegetatives Dämpfungsmittel bei psychischen Störungen. Schweiz Med Wochenschr 83: 581–586

    CAS  PubMed  Google Scholar 

  • Stolk P, Ten Berg MJ, Hemels ME, Einarson TR (2003) Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother. 37: 1891–1899

    Article  PubMed  Google Scholar 

  • Stone M, Laughren T, Jones ML et al (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339: b2880

    Article  PubMed Central  PubMed  Google Scholar 

  • Storosum JG, von Zweiten BJ, Van Den Brink W et al (2001) Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 158: 1271–1275

    Article  CAS  PubMed  Google Scholar 

  • Stroup TS, Alves WM, Hamer RM, Lieberman JA (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Rev Drug Discov 5: 133–146

    Article  CAS  Google Scholar 

  • Temple R, Ellenberg SS (2000) Placebo-controlled trials and active control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 133: 455–463

    Article  CAS  PubMed  Google Scholar 

  • Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840–1847

    Article  PubMed  Google Scholar 

  • Wampold BE, Minami T, Tierney SC et al (2005) The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol 81: 835–854

    Article  Google Scholar 

  • Zipursky RB, Darby P (1999) Placebo-controlled studies in schizophrenia – ethical and scientific perspectives: an overview of conference proceedings. Schizophr Res 35: 189–200

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. RPS Research Germany GmbH, Scheurlstr. 21, 90478, Nürnberg

    PD Dr. Dipl.-Psych. Ralf Kohnen

  2. Neurologische Klinik, Somni bene Institut für Medizinische Forschung, Universität Rostock, Schlafmedizin Schwerin GmbH, Arsenalstraße 10, 19055, Schwerin

    Dr. MU Dr. Heike Beneš

  3. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn

    Dr. Karl Broich

  4. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn

    Dr. Thomas Fischer

Authors
  1. PD Dr. Dipl.-Psych. Ralf Kohnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. MU Dr. Heike Beneš
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. Karl Broich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. Thomas Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Pauwelsstr. 30, 52074, Aachen

    Gerhard Gründer

  2. Luisenstr. 19, 55124, Mainz

    Otto Benkert

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kohnen, R., Beneš, H., Broich, K., Fischer, T. (2012). Studien mit Psychopharmaka. In: Gründer, G., Benkert, O. (eds) Handbuch der psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19844-1_49

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-19844-1_49

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-19843-4

  • Online ISBN: 978-3-642-19844-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation